37,114 Shares in Immunome, Inc. $IMNM Acquired by Walleye Capital LLC

Key Points

• Walleye Capital LLC has taken a new position in Immunome, Inc. by purchasing 37,114 shares valued at approximately $250,000 in the first quarter of this year.
• Immunome's stock has declined by 4.4% and currently trades at $9.80, with a market capitalization of approximately $852.99 million.
• Analysts have issued a consensus rating of "Buy" for Immunome, with an average target price set at $22.50, indicating potential growth in the future.

Walleye Capital LLC acquired a new stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 37,114 shares of the company's stock, valued at approximately $250,000.

Other institutional investors have also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets purchased a new stake in Immunome during the fourth quarter worth about $70,000. Tower Research Capital LLC TRC boosted its holdings in Immunome by 482.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock worth $91,000 after buying an additional 7,129 shares in the last quarter. ANTIPODES PARTNERS Ltd purchased a new stake in Immunome during the first quarter worth about $95,000. KLP Kapitalforvaltning AS boosted its holdings in Immunome by 140.8% during the first quarter. KLP Kapitalforvaltning AS now owns 17,100 shares of the company's stock worth $115,000 after buying an additional 10,000 shares in the last quarter. Finally, Teacher Retirement System of Texas boosted its holdings in Immunome by 49.0% during the first quarter. Teacher Retirement System of Texas now owns 17,360 shares of the company's stock worth $117,000 after buying an additional 5,712 shares in the last quarter. Hedge funds and other institutional investors own 44.58% of the company's stock.

Immunome Stock Down 2.3%

Shares of NASDAQ:IMNM traded down $0.21 during trading on Wednesday, reaching $9.00. The stock had a trading volume of 800,424 shares, compared to its average volume of 760,686. The business has a fifty day moving average price of $9.91 and a 200-day moving average price of $8.84. The stock has a market cap of $783.36 million, a P/E ratio of -2.92 and a beta of 1.92. Immunome, Inc. has a fifty-two week low of $5.15 and a fifty-two week high of $16.73.

Immunome (NASDAQ:IMNM - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.52) by $0.02. Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.10%. The business had revenue of $4.02 million during the quarter, compared to analyst estimates of $1.03 million. As a group, equities analysts forecast that Immunome, Inc. will post -2.21 EPS for the current year.

Wall Street Analysts Forecast Growth

IMNM has been the topic of a number of research analyst reports. Wedbush reissued an "outperform" rating and set a $21.00 price objective on shares of Immunome in a report on Thursday, August 7th. Guggenheim reissued a "buy" rating and set a $25.00 price objective on shares of Immunome in a report on Monday, August 25th. Evercore ISI initiated coverage on shares of Immunome in a report on Friday, August 22nd. They set an "outperform" rating and a $18.00 price objective on the stock. JPMorgan Chase & Co. decreased their price objective on shares of Immunome from $23.00 to $22.00 and set an "overweight" rating on the stock in a report on Thursday, August 7th. Finally, Wall Street Zen upgraded shares of Immunome from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Nine research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $22.89.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.